Polymyalgia Rheumatica.
Journal
Deutsches Arzteblatt international
ISSN: 1866-0452
Titre abrégé: Dtsch Arztebl Int
Pays: Germany
ID NLM: 101475967
Informations de publication
Date de publication:
17 06 2022
17 06 2022
Historique:
received:
15
02
2022
revised:
15
02
2022
accepted:
02
05
2022
pubmed:
1
6
2022
medline:
20
9
2022
entrez:
31
5
2022
Statut:
ppublish
Résumé
Polymyalgia rheumatica (PMR) is among the most common inflammatory rheumatic diseases in older adults. Presumed risk factors include female sex, previous infections, and genetic factors. No epidemiological data on PMR in Germany have been available until now. This review is based on publications retrieved by a selective literature search in PubMed. Moreover, the administrative incidence and prevalence of PMR in the years 2011-2019 was determined from data of the AOK Baden-Württemberg statutory health insurance carrier for insurees aged 40 and older. In addition, we quantified the number of consultations with physicians involved in the diagnosis. The annual age- and sex-standardized incidence and prevalence of PMR from 2011 to 2019 were 18.6/100 000 persons and 138.8/100 000 persons, respectively. The incidence was higher in women than in men (21.8/100 000 vs. 12.8/100 000 persons per year). 60% of the cases were diagnosed in primary care practices. The treatment of PMR with orally administered glucocorticoids usually results in a treatment response within a few days to weeks. Approximately 43% of patients experience recurrent symptoms within a year, requiring adjustment of the glucocorticoid dose. For older patients with impaired physical ability, additional non-pharmacological treatment with exercise programs plays an important role. PMR usually takes an uncomplicated course under treatment and can be managed in primary care, but these patients are often multimorbid and require frequent follow-up. Along with research on the etiology of the disease, further studies are needed to identify the risk factors for a chronic course and to evaluate the potential effects of non-pharmacological measures.
Sections du résumé
BACKGROUND
Polymyalgia rheumatica (PMR) is among the most common inflammatory rheumatic diseases in older adults. Presumed risk factors include female sex, previous infections, and genetic factors. No epidemiological data on PMR in Germany have been available until now.
METHODS
This review is based on publications retrieved by a selective literature search in PubMed. Moreover, the administrative incidence and prevalence of PMR in the years 2011-2019 was determined from data of the AOK Baden-Württemberg statutory health insurance carrier for insurees aged 40 and older. In addition, we quantified the number of consultations with physicians involved in the diagnosis.
RESULTS
The annual age- and sex-standardized incidence and prevalence of PMR from 2011 to 2019 were 18.6/100 000 persons and 138.8/100 000 persons, respectively. The incidence was higher in women than in men (21.8/100 000 vs. 12.8/100 000 persons per year). 60% of the cases were diagnosed in primary care practices. The treatment of PMR with orally administered glucocorticoids usually results in a treatment response within a few days to weeks. Approximately 43% of patients experience recurrent symptoms within a year, requiring adjustment of the glucocorticoid dose. For older patients with impaired physical ability, additional non-pharmacological treatment with exercise programs plays an important role.
CONCLUSION
PMR usually takes an uncomplicated course under treatment and can be managed in primary care, but these patients are often multimorbid and require frequent follow-up. Along with research on the etiology of the disease, further studies are needed to identify the risk factors for a chronic course and to evaluate the potential effects of non-pharmacological measures.
Identifiants
pubmed: 35635433
pii: arztebl.m2022.0218
doi: 10.3238/arztebl.m2022.0218
pmc: PMC9533703
doi:
pii:
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
411-417Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Rheumatol Int. 2018 Apr;38(4):569-577
pubmed: 29124397
Arthritis Rheum. 2011 Mar;63(3):633-9
pubmed: 21360492
Z Rheumatol. 2018 Jun;77(5):429-441
pubmed: 29845555
Arthritis Rheum. 2009 Sep 15;61(9):1264-7
pubmed: 19714587
J Rheumatol. 1996 Jan;23(1):112-9
pubmed: 8838518
Rheumatology (Oxford). 2019 May 1;58(5):921-923
pubmed: 30649507
Arthritis Care Res (Hoboken). 2017 Aug;69(8):1282-1285
pubmed: 27768840
Drugs Aging. 2019 Nov;36(11):1015-1026
pubmed: 31493201
Clin Rheumatol. 2000;19(4):278-80
pubmed: 10941808
Autoimmun Rev. 2020 Nov;19(11):102670
pubmed: 32942037
Curr Rheumatol Rep. 2020 Jun 19;22(8):40
pubmed: 32562020
Med Sci (Basel). 2019 Aug 30;7(9):
pubmed: 31480261
Arthritis Rheum. 2012 Apr;64(4):943-54
pubmed: 22389040
Br J Gen Pract. 2013 May;63(610):e361-6
pubmed: 23643235
Best Pract Res Clin Rheumatol. 2018 Apr;32(2):271-294
pubmed: 30527432
Ann Intern Med. 2017 May 2;166(9):ITC65-ITC80
pubmed: 28460395
Open Access Rheumatol. 2016 Oct 17;8:93-95
pubmed: 27843375
Clin Rheumatol. 2022 Jan;41(1):19-31
pubmed: 34415462
Rheumatology (Oxford). 2017 Apr 1;56(4):506-515
pubmed: 27481272
Ann Rheum Dis. 2015 Oct;74(10):1799-807
pubmed: 26359488
Arthritis Rheum. 2005 Feb 15;53(1):33-8
pubmed: 15696567
Z Rheumatol. 2012 Dec;71(10):911-2
pubmed: 23090090
Arthritis Res Ther. 2018 Nov 20;20(1):258
pubmed: 30458857
JAMA. 2016 Jun 14;315(22):2442-58
pubmed: 27299619
J Health Econ. 2017 Dec;56:397-413
pubmed: 29248063
Lancet. 2017 Oct 7;390(10103):1700-1712
pubmed: 28774422
Z Rheumatol. 2014 Jun;73(5):408-14
pubmed: 24924726
Reumatologia. 2018;56(3):131-139
pubmed: 30042600
Arthritis Rheum. 2009 Oct 15;61(10):1454-61
pubmed: 19790127
J Rheumatol. 1999 Feb;26(2):361-9
pubmed: 9972970
Semin Arthritis Rheum. 2000 Aug;30(1):17-24
pubmed: 10966209
Ann Rheum Dis. 2018 Dec;77(12):1750-1756
pubmed: 30297332